Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 2/2010

01.04.2010 | Vascular Disease

Complex Regional Pain Syndrome: State of the Art Update

verfasst von: Patrick Henson, DO, Stephen Bruehl, PhD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Opinion statement

Although the pathophysiology of complex regional pain syndrome (CRPS) is not fully understood, it appears to reflect multiple interacting mechanisms. In addition to altered autonomic function, a role for inflammatory mechanisms and altered somatosensory and motor function in the brain is increasingly suggested. Several possible risk factors for development of CRPS, including genetic factors, have been identified. Few treatments have been proven effective for CRPS in well-designed clinical trials. However, recent work suggests that bisphosphonates may be useful in CRPS management and that the N-methyl-d-aspartate receptor antagonist ketamine significantly reduces CRPS pain when administered topically or intravenously at subanesthetic dosages. Extended use of ketamine at anesthetic dosages (“ketamine coma”) remains a controversial and unproven treatment for CRPS. Spinal cord stimulation may be effective for reducing pain in approximately two thirds of CRPS patients not responding to other treatments, but its efficacy appears to diminish over time.
Literatur
1.
Merskey H, Bogduk N: Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, edn 2. Seattle: IASP Press; 1994.
2.
Cheng JK, Ji RR: Intracellular signaling in primary sensory neurons and persistent pain. Neurochem Res 2008, 33:1970–1978.CrossRefPubMed
3.
4.
Vaneker M, van der Laan L, Allebes WA, Goris J: Genetic factors associated with Complex Regional Pain Syndrome I: HLA DRB and TNF alpha promoter gene polymorphism. Disabil Med 2002, 2:69–74.
5.
Kemler MA, van de Vusse AC, van den Berg-Loonen EM, et al.: HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology 1999, 53:1350–1351.PubMed
6.
van Hilten JJ, van de Beek WJ, Roep BO: Multifocal or generalized tonic dystonia of complex regional pain syndrome: a distinct clinical entity associated with HLA-DR13. Ann Neurol 2000, 48:113–116.CrossRefPubMed
7.
de Rooij AM, FlorenciaGosso M, Haasnoot GW, et al.: HLA-B62 and HLA-DQ8 are associated with Complex Regional Pain Syndrome with fixed dystonia. Pain 2009, 145:82–85.CrossRefPubMed
8.
Devor M: Nerve pathophysiology and mechanisms of pain in causalgia. J Auton Nerv Syst 1983, 7:371–384.CrossRefPubMed
9.
Jänig W, Baron R: The role of the sympathetic nervous system in neuropathic pain: clinical observations and animal models. In Neuropathic Pain: Pathophysiology and Treatment. Edited by Hansson PT, Fields HL, Hill RG, Marchettini P. Seattle: IASP Press; 2001.
10.
Schürmann M, Gradl G, Zaspel J, et al.: Peripheral sympathetic function as a predictor of complex regional pain syndrome type I (CRPS I) in patients with radial fracture. Auton Neurosci 2000, 86:127–134.CrossRefPubMed
11.
Harden RN, Rudin NJ, Bruehl S, et al.: Increased systemic catecholamines in complex regional pain syndrome and relationship to psychological factors: a pilot study. Anesth Analg 2004, 99:1478–1485.CrossRefPubMed
12.
Koban M, Leis S, Schultze-Mosgau S, Birklein F: Tissue hypoxia in complex regional pain syndrome. Pain 2003, 104:149–157.CrossRefPubMed
13.
Ji RR, Woolf CJ: Neuronal plasticity and signal transduction in nociceptive neurons: implications for the initiation and maintenance of pathological pain. Neurobiol Dis 2001, 8:1–10.CrossRefPubMed
14.
Juottonen K, Gockel M, Silén T, et al.: Altered central sensorimotor processing in patients with complex regional pain syndrome. Pain 2002, 98:315–323.CrossRefPubMed
15.
Maihöfner C, Handwerker HO, Neundörfer B, Birklein F: Patterns of cortical reorganization in complex regional pain syndrome. Neurology 2003, 61: 1707–1715.PubMed
16.
Maihöfner C, Handwerker HO, Neundörfer B, Birklein F: Cortical reorganization during recovery from complex regional pain syndrome. Neurology 2004, 63:693–701.PubMed
17.
Pleger B, Ragert P, Schwenkreis P, et al.: Patterns of cortical reorganization parallel impaired tactile discrimination and pain intensity in complex regional pain syndrome. Neuroimage 2006, 32:503–510.CrossRefPubMed
18.
Pleger B, Tegenthoff M, Ragert P, et al.: Sensorimotor retuning in complex regional pain syndrome parallels pain reduction. Ann Neurol 2005, 57:425–429.CrossRefPubMed
19.
Florence SL, Taub HB, Kaas JH: Large-scale sprouting of cortical connections after peripheral injury in adult macaque monkeys. Science 1998, 282:1117–1121.CrossRefPubMed
20.
de Mos M, Huygen FJ, Dieleman JP, et al.: Medical history and the onset of complex regional pain syndrome (CRPS). Pain 2008, 139(2):458–466.CrossRefPubMed
21.
de Mos M, Huygen FJ, Stricker BH, et al.: Estrogens and the risk of complex regional pain syndrome (CRPS). Pharmacoepidemiol Drug Saf 2009, 18(1):44–52.CrossRefPubMed
22.
Peterlin BL, Rosso AL, Nair S, et al.: Migraine may be a risk factor for the development of complex regional pain syndrome. Cephalalgia 2009 Jul 9 (Epub ahead of print).
23.
de Mos M, de Bruijn AGJ, Huygen FJPM, et al.: The incidence of complex regional pain syndrome: a population-based study. Pain 2007, 129:12–20.CrossRefPubMed
24.
Sandroni P, Benrud-Larson LM, McClelland RL, Low PA: Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain 2003, 103:199–207.CrossRefPubMed
25.
de Mos M, Huygen FJ, Stricker BH, et al.: The association between ACE inhibitors and the complex regional pain syndrome: suggestions for a neuro-inflammatory pathogenesis of CRPS. Pain 2009, 142(3):218–224.CrossRefPubMed
26.
Higashimoto T, Baldwin EE, Gold JI, Boles RG: Reflex sympathetic dystrophy: complex regional pain syndrome type I in children with mitochondrial disease and maternal inheritance. Arch Dis Child 2008, 93(5):390–397.CrossRefPubMed
27.
de Rooij AM, de Mos M, Sturkenboom MC, et al.: Familial occurrence of complex regional pain syndrome. Eur J Pain 2009, 13(2):171–177.CrossRefPubMed
28.
Kemler MA, van de Vusse AC, van den Berg-Loonen EM, et al.: HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology 1999, 53(6):1350–1351.PubMed
29.
Vaneker M, van der Laan L, Allebes WA, Goris RJA: Genetic factors associated with complex regional pain syndrome 1: HLA DRB and TNF alpha promotor gene polymorphism. Disabil Med 2002, 2(3):69–74.
30.
van Hilten JJ, van de Beek WJ, Roep BO: Multifocal or generalized tonic dystonia of complex regional pain syndrome: a distinct clinical entity associated with HLA-DR13. Ann Neurol 2000, 48(1):113–116.CrossRefPubMed
31.
de Rooij AM, Florencia Gosso M, Haasnoot GW, et al.: HLA-B62 and HLA-DQ8 are associated with Complex Regional Pain Syndrome with fixed dystonia. Pain 2009, 145(1–2):82–85.CrossRefPubMed
32.
Tan EC, van de Sandt-Renkema N, et al.: Quality of life in adults with childhood-onset of Complex Regional Pain Syndrome type I. Injury 2009, 40(8):901–904.CrossRefPubMed
33.
Sherry DD, Wallace CA, Kelley C, et al.: Short- and long-term outcomes of children with complex regional pain syndrome type I treated with exercise therapy. Clin J Pain 1999, 15:218–223.CrossRefPubMed
34.
Schinkel C, Scherens A, Köller M, et al.: Systemic inflammatory mediators in post-traumatic complex regional pain syndrome (CRPS I)—longitudinal investigations and differences to control groups. Eur J Med Res 2009, 14(3):130–135.PubMed
35.
Del Valle L, Schwartzman RJ, Alexander G: Spinal cord histopathological alterations in a patient with longstanding complex regional pain syndrome. Brain Behav Immun 2009, 23(1):85–91.CrossRefPubMed
36.
Kohr D, Tschernatsch M, Schmitz K, et al.: Autoantibodies in complex regional pain syndrome bind to a differentiation-dependent neuronal surface autoantigen. Pain 2009, 143(3):246–251.CrossRefPubMed
37.
Li WW, Sabsovich I, Guo TZ, et al.: The role of enhanced cutaneous IL-1beta signaling in a rat tibia fracture model of complex regional pain syndrome. Pain 2009, 144(3):303–313.CrossRefPubMed
38.
Sabsovich I, Guo TZ, Wei T, et al.: TNF signaling contributes to the development of nociceptive sensitization in a tibia fracture model of complex regional pain syndrome type I. Pain 2008, 137(3):507–519.CrossRefPubMed
39.
Wei T, Sabsovich I, Guo TZ, et al.: Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 2009, 13(3):253–262.CrossRefPubMed
40.
Sabsovich I, Wei T, Guo TZ, et al.: Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain 2008, 138(1):47–60.CrossRefPubMed
41.
Wei T, Li WW, Guo TZ, et al.: Post-junctional facilitation of Substance P signaling in a tibia fracture rat model of complex regional pain syndrome type I. Pain 2009, 144(3):278–286.CrossRefPubMed
42.
Chung OY, Bruehl SP: Complex regional pain syndrome. Curr Treat Options Neurol 2003, 5(6):499–511.CrossRef
43.
Muizelaar JP, Kleyer M, Hertogs IAM, Delange DC: Complex regional syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha sympathetic blocker phenoxybenzamine in 59 patients. Clin Neurol Neurosurg 1997, 99:26–30.CrossRefPubMed
44.
Ghostine SY, Comair YG, Turner DM, et al.: Phenoxybenzamine in the treatment of causalgia. Report of 40 cases. J Neurosurg 1984, 60:1263–1268.CrossRefPubMed
45.
Davis KD, Treede RD, Raja SN, et al.: Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain 1991, 47:309–317.CrossRefPubMed
46.
Stanton-Hicks MD, Burton AW, Bruehl SP, et al.: Complex Regional Pain Syndromes: updated interdisciplinary clinical pathway: report of an expert panel. Pain Pract 2002, 2:1–16.CrossRefPubMed
47.
Oerlemans HM, Oostendorp RAB, de Boo T, Goris RJA: Pain and reduced mobility in complex regional pain syndrome I: outcome of a prospective randomized controlled clinical trial of adjuvant physical therapy versus occupational therapy. Pain 1999, 83:77–83.CrossRefPubMed
48.
Moseley GL, Wiech K: The effect of tactile discrimination training is enhanced when patients watch the reflected image of their unaffected limb during training. Pain 2009, 144(3):314–319.CrossRefPubMed
49.
Christensen K, Jensen EM, Noer I: The reflex dystrophy syndrome response to treatment with systemic corticosteroids. Acta Chir Scand 1982, 148:653–655.PubMed
50.
Braus DF, Krauss JK, Strobel J: The shoulder-hand syndrome after stroke: a prospective clinical trial. Ann Neurol 1994, 36:728–733.CrossRefPubMed
51.
Sindrup SH, Jensen ST. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999, 83:389–400.CrossRefPubMed
52.
Collins SL, Moore RA, McQuay HJ, Wiffen P: Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 2000, 20:449–458.CrossRefPubMed
53.
Wiffen P, Collins S, McQuay H, et al.: Anticonvulsant drugs for acute and chronic pain. Cochrane Database Sys Rev 2000, 3:CD001133.
54.
van de Vusse AC, Stomp-van den Berg SG, Kessels AH, Weber WE: Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379]. BMC Neurol 2004, 4:13.CrossRefPubMed
55.
McQuay HJ, Tramer M, Nye BA, et al.: A systematic review of antidepressants in neuropathic pain. Pain 1996, 68:217–227.CrossRefPubMed
56.
Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998, 50:1837–1841.PubMed
57.
Dellemijn PL, Van Duijn H, Vanneste JA: Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998, 16:220–229.CrossRefPubMed
58.
Cherny NI, Thaler HT, Klar HF, et al.: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single dose studies. Neurology 1994, 44:857–861.PubMed
59.
Harke H, Gretenkort P, Ladleif HU, et al.: The response of neuropathic pain and pain in complex regional pain syndrome I to carbamazepine and sustained-release morphine in patients pretreated with spinal cord stimulation: a double-blinded randomized study. Anesth Anal 2001, 92:488–495.CrossRef
60.
Gilron I, Bailey JM, Tu D, et al.: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324–1334.CrossRefPubMed
61.
Price DD, Long S, Wilsey B, Rafii A: Analysis of peak magnitude and duration of analgesia produced by local anesthetics injected into sympathetic ganglia of complex regional pain syndrome patients. Clin J Pain 1998, 14:216–226.CrossRefPubMed
62.
Perez RSGM, Kwakkel G, Zuurmond WWA, de Lange JJ: Treatment of reflex sympathetic dystrophy (CRPS Type I): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage 2001, 21:511–526.CrossRefPubMed
63.
Hanna MH, Peat SJ: Ketanserin in reflex sympathetic dystrophy: a double-blind placebo-controlled crossover trial. Pain 1989, 38:145–150.CrossRefPubMed
64.
Hord AH, Rooks MD, Stephens BO, et al.: Intravenous regional bretylium and lidocaine for treatment of reflex sympathetic dystrophy: a randomized, double-blind study. Anesth Analg 1992, 74:818–821.CrossRefPubMed
65.
Morley S, Eccleston C, Williams A: Systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy and behavior therapy for chronic pain in adults, excluding headache. Pain 1999, 80:1–13.CrossRefPubMed
66.•
Kemler MA, de Vet HC, Barendse GA, et al.: Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial. J Neurosurg 2008, 108(2):292–298.CrossRefPubMed
67.
Sigtermans MJ, van Hilten JJ, Bauer MC, et al.: Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. Pain 2009, 145(3):304–311.CrossRefPubMed
68.
Sigtermans M, Noppers I, Sarton E, et al.: An observational study on the effect of S(+)-ketamine on chronic pain versus experimental acute pain in Complex Regional Pain Syndrome type 1 patients. Eur J Pain 2009 Jun 17 (Epub ahead of print).
69.
Kiefer RT, Rohr P, Ploppa A, et al.: Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med 2008, 9(8):1173–1201.CrossRefPubMed
70.•
Finch PM, Knudsen L, Drummond PD: Reduction of allodynia in patients with complex regional pain syndrome: a double-blind placebo-controlled trial of topical ketamine. Pain 2009, 146(1–2):18–25.CrossRefPubMed
71.•
Brunner F, Schmid A, Kissling R, et al.: Bisphosphonate for the therapy of complex regional pain syndrome I—systematic review. Eur J Pain 2009, 13(1):17–21.CrossRefPubMed
72.
Breuer B, Pappagallo M, Ongseng F, et al.: An open-label pilot trial of ibandronate for complex regional pain syndrome. Clin J Pain 2008, 24(8):685–689.CrossRefPubMed
73.
Munts AG, van der Plas AA, Voormolen JH, et al.: Intrathecal glycine for pain and dystonia in complex regional pain syndrome. Pain 2009, 146(1–2):199–204.CrossRefPubMed
74.
van Rijn MA, Munts AG, Marinus J, et al.: Intrathecal baclofen for dystonia of complex regional pain syndrome. Pain 2009, 143(1–2):41–47.CrossRefPubMed
Metadaten
Titel
Complex Regional Pain Syndrome: State of the Art Update
verfasst von
Patrick Henson, DO
Stephen Bruehl, PhD
Publikationsdatum
01.04.2010
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 2/2010
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-010-0063-z

Weitere Artikel der Ausgabe 2/2010

Current Treatment Options in Cardiovascular Medicine 2/2010 Zur Ausgabe

Vascular Disease

Chronic Thromboembolic Pulmonary Hypertension

Vascular Disease

Venous Leg Ulcerations: A Treatment Update

Vascular Disease

New and Emerging Anticoagulant Therapies for Venous Thromboembolism

Vascular Disease

Management of Pulmonary Embolism: 2010 State-of-the-Art Update

Vascular Disease

Management of Raynaud’s Phenomenon in the Patient with Connective Tissue Disease

Vascular Disease

Current Concepts in the Management of Chronic Mesenteric Ischemia

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen